Laura Orlando, Managing Partner in our Milan office has been interviewed by Managing IP (MIP), regarding which city will replace London as the site of the central division seat for the UPC dealing with pharmaceutical matters.
Laura's comments include:
The question of which city, if any, will replace London is ultimately a political one, and it will require a diplomatic effort on the part of the successful candidate’s government to secure the seat.
MIP reports that, "in Orlando’s opinion, the Italian state’s historic lack of interest in IP represents a “huge risk” to Milan’s candidacy" and that "the danger, she argues, is that any lack of engagement from the Italian government will simply result in Munich and Paris – the two current hosts – remaining as the only two central division seats".
You can read the full article on the Managing IP website here.
Key contacts
Laura Orlando
Italy Managing Partner, Joint Global Head of Intellectual Property, EMEA Co-Head of Life Sciences, Milan
Disclaimer
The articles published on this website, current at the dates of publication set out above, are for reference purposes only. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action.